NASDAQ NMS - GLOBAL MARKET · MRVI
+0.46% · +$0.0324 · Vol 2.8M
Market closed · last close 4:00 PM ET · price as of 19:14:17 ET
Maravai LifeSciences Holdings Inc

Maravai LifeSciences Holdings Inc

Life Sciences Tools & Services
$7.12
Card
Relationship Map

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

Score not reportedVeridion does not publish a score-history trend for MRVI until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
NO SCORE SNAPSHOT COVERAGE
AI Analysis
Sovereign

Why is MRVI moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for MRVI are being assembled.
About Maravai LifeSciences Holdings Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
416
Country
US

Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$6.91
Day high
$7.25
Day low
$6.81
Previous close
$7.09
52W high
$7.25
-1.83% from high
52W low
$2.02
97% of range
Market cap
$1B
EPS
$-0.6800
Beta
1.18
Shares out
147.5M
Volume
2.8M
0.85× rel vol
Avg volume
3.4M
VWAP
$7.13
Price history computed in-house
1W
+16.95%
1M
+36.97%
3M
+110.10%
1Y
+193.10%
YTD
+119.15%
SMA 50 $5.25 · above
SMA 200 $3.84 · above
52W position 97%
Veridion warehouse edge

Warehouse intelligence for MRVI.

Veridion Score
Not reported
Six-factor detail requires Sovereign.
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Related public evidence

Continue the MRVI research trail.

Relationship mapTrace receipt-backed holders and filings around MRVI.Congress disclosuresOpen receipt and filing context for MRVI.MethodologyReview score inputs, coverage rules, and limitations.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

Receipt-backed filing rows for MRVI are being assembled from the latest scheduled snapshot.

Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

MRVI contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for MRVI in this window.
Lobbying spend

MRVI lobbying filings, year to date.

Registered lobbying filings matched to Maravai LifeSciences Holdings Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for MRVI in this window.
Latest news · MRVI
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for MRVI.
Options
Sovereign unlock shows live options positioning for MRVI.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.